请输入关键字
请输入关键字
订购
*国家
中国
美国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-hTIGIT mice
Strain Name C57BL/6-Tigittm1(TIGIT)/Bcgen Common Name  B-hTIGIT mice
Background C57BL/6 Catalog number  110017
Related Genes 
TIGIT(T cell immunoreceptor with Ig and ITIM domains)

Gene description

TIGIT (T-cell immunoreceptor with Ig and ITIM domains), a member of the immunoglobulin family of PVR (poliovirus receptor), is a type I transmembrane protein. Similar to PD-1, TIM3, and LAG3, TIGIT is highly expressed in cancer tissues and competitively binds to TIGIT receptors with DNAM-1 proteins on the surface of NK cells to reduce the NK cell killing efficiency of cancer cells. Therefore, anti-TIGIT antibody can enhance NK cell ability to destroy tumor cells by facilitating DNAM-1 binding to TIGIT receptors. It has become the new generation of cancer immunotherapy checkpoint.


Protein expression analysis


from clipboard


Strain specific TIGIT expression analysis in homozygous B-hTIGIT mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hTIGIT (H/H) mice stimulated with anti-CD3ε in vivo (7.5 µg/mice), and analyzed by flow cytometry with species-specific anti-TIGIT antibody. Mouse TIGIT was exclusively detected in WT mice. Human TIGIT were exclusively detected in homozygous B-hTIGIT mice (H/H) but not WT mice.


In vivo efficacy of Tiragolumab(in house)

from clipboard

Antitumor activity of anti-human TIGIT antibodies in B-hTIGIT mice. (A) Anti-human TIGIT antibodies inhibited MC38 tumor growth in B-hTIGIT mice. Murine colon cancer MC38 cells (5ⅹ105) were subcutaneously implanted into homozygous B-hTIGIT mice (female, 8 week-old, n=6). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-human TIGIT antibodies with different doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, anti-human TIGIT antibodies were efficacious in controlling tumor growth in B-hTIGIT mice, demonstrating that the B-hTIGIT mice provide a powerful preclinical model for in vivo evaluation of anti-human TIGIT antibodies. Values are expressed as mean ± SEM


In vivo efficacy of anti-human TIGIT antibodies

from clipboard
Antitumor activity of anti-human TIGIT antibodies in B-hTIGIT mice. (A) Anti-human TIGIT antibodies inhibited MC38 tumor growth in B-hTIGIT mice. Murine colon cancer MC38 cells (1ⅹ106) were subcutaneously implanted into homozygous B-hTIGIT mice (female, 7 week-old, n=7). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with two anti-human TIGIT antibodies and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, anti-human TIGIT antibodies were efficacious in controlling tumor growth in B-hTIGIT mice, demonstrating that the B-hTIGIT mice provide a powerful preclinical model for in vivo evaluation of anti-human TIGIT antibodies. Values are expressed as mean ± SEM